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Abstract Since the development ofthe RadiationTherapy
Oncology Group-Recursive Partitioning Analysis (RTOG-
RPA)riskclassesforhigh-gradeglioma,radiationtherapyin
combination with temozolomide (TMZ) has become stan-
dard care. While this combination has improved survival,
the prognosis remains poor in the majority of patients.
Therefore, strong interest in high-grade gliomas from basic
research to clinical trials persists. We sought to evaluate
whether the current RTOG-RPA retains prognostic
signiﬁcanceintheTMZeraoralternatively,ifmodiﬁcations
better prognosticate the optimal selection of patients with
similar baseline prognosis for future clinical protocols. The
records of 159 patients with newly-diagnosed glioblastoma
(GBM, WHO grade IV) or anaplastic astrocytoma (AA,
WHO grade III) were reviewed. Patients were treated with
intensity-modulated radiation therapy (IMRT) and concur-
rent followed by adjuvant TMZ (n = 154) or adjuvant TMZ
only (n = 5). The primary endpoint was overall survival.
Three separate analyses were performed: (1) application of
RTOG-RPA to the study cohort and calculation of sub-
sequent survival curves, (2) ﬁt a new tree model with the
same predictors in RTOG-RPA, and (3) ﬁt a new tree model
with an expanded predictor set. All analyses used a regres-
sion tree analysis with a survival outcome ﬁt to formulate
new risk classes. Overall median survival was 14.9 months.
Using the RTOG-RPA, the six classes retained their relative
prognostic signiﬁcance and overall ordering, with the cor-
responding survival distributions signiﬁcantly different
fromeachother(P\0.01,v
2statistic = 70).Newrecursive
partitioning limited to the predictors in RTOG-RPA deﬁned
four risk groups based on Karnofsky Performance Status
(KPS), histology, age, length of neurologic symptoms, and
mental status. Analysis across the expanded predictors
deﬁned six risk classes, including the same ﬁve variables
plus tumor location, tobacco use, and hospitalization during
radiation therapy. Patients with excellent functional status,
AA, and frontal lobe tumors had the best prognosis. For
patients with newly-diagnosed high-grade gliomas, RTOG-
RPA classes retained prognostic signiﬁcance in patients
treated with TMZ and IMRT. In contrast to RTOG-RPA, in
our modiﬁed RPA model, KPS rather than age represented
the initial split. New recursive partitioning identiﬁed
potentialmodiﬁcationstoRTOG-RPAthatshouldbefurther
explored with a larger data set.
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Introduction
High-grade gliomas, glioblastoma (GBM) and anaplastic
astrocytoma (AA), are the most common and most
malignant brain tumors in adults. Prior to the development
of temozolomide (TMZ), the survival of patients with high-
grade gliomas had not improved signiﬁcantly. Extent of
surgical resection and adjuvant radiation have been shown
in several clinical trials from the 1970s to the 1990s to be
the best predictors of outcomes, leading to wide recogni-
tion of these modalities as standard therapy [1]. However,
trials of adjuvant chemotherapy in the pre-temozolomide
era were equivocal, including a meta-analysis of 12 ran-
domized clinical trials that showed only a small survival
beneﬁt [2]. Over the past decade, several trials of novel
biologic or other therapeutic interventions, excluding those
of TMZ, have shown little impact on survival compared to
the pretreatment and treatment-related factors described in
the recursive partitioning analysis by Curran et al. [3, 4].
The division of high-grade glioma patients into prognostic
groups formed from recursive partitioning across these
pretreatment and treatment-related prognostic variables has
proven valuable in myriad clinical trials [4–14].
For patients treated with radiation therapy only, the
Radiation Therapy Oncology Group-Recursive Partitioning
Analysis (RTOG-RPA) was developed to obtain groups of
patients with similar survival times [3]. Because the sur-
vival of high-grade glioma patients remains relatively poor,
there has been a sustained interest in developing phase II
protocols. RTOG-RPA has been used extensively in the
design and interpretation of phase II protocols and for
reﬁning stratiﬁcation in phase III trials [5, 6, 8–17].
The principle advantage of using a recursive partitioning
model to analyze survival is that tree models yield a more
clinically interpretable result, and interactions and non-
linearity are implicitly ﬁt in the model. While the propor-
tional hazards model provides relative risks based on
patient characteristics, it does not translate into deﬁned
survival-based risk classes amendable to evaluating the
efﬁcacy of a therapy.
Prior to the TMZ era, RTOG-RPA was validated in two
published series [4, 7]. However in recent years, TMZ was
repeatedly shown to unequivocally improve overall sur-
vival of patients when given concurrently with radiation
therapy and as adjuvant [16–18]. The acceptance of TMZ
as standard treatment for high-grade glioma patients was a
signiﬁcant change in therapy following the development of
the RTOG-RPA in 1993. In this context, we have con-
ducted a validation study of RTOG-RPA to determine if it
retains prognostic value in high-grade glioma patients
treated with TMZ in addition to intensity-modulated radi-
ation therapy (IMRT) in patients with GBM and AA. We
also report modiﬁcations to the existing RTOG-RPA that
increased its prognostic value in our patients.
Methods
This study was approved by the University of Pittsburgh
Cancer Institute’s Institutional Review Board. One hundred
seventy-six (176) patients with newly-diagnosed high-grade
glioma who were treated with IMRT generated from Eclip-
se
TM TPS (Varian Medical Systems, Palo Alto, CA) and
TMZ between March 2004 and March 2009 were identiﬁed.
In all cases, diagnosis was established by pathology review
at the University of Pittsburgh Medical Centers. Patients
with cerebellar (n = 6), brainstem (n = 5), pineal (n = 3)
oroptictumors(n = 3)wereexcludedfromfurtheranalysis.
The remaining 159 patients were treated with IMRT and
concurrent followed by adjuvant TMZ (n = 154) or adju-
vant TMZ only (n = 5). All data included in this analysis
wereextractedfromthepaperandelectronicmedicalrecords
with blinding to patients’ date of death and last follow-up.
Three separate analyses were conducted. The ﬁrst, val-
idation of RTOG-RPA, was completed by assigning
RTOG-RPA risk class to each patient in our cohort
(Fig. 1). We subsequently determined if the Kaplan–Meier
survival curves of RTOG-RPA risk classes were signiﬁ-
cantly different from each other using the Harrington–
Fleming test in R statistical software [19].
The second analysis again used only the covariates in
RTOG-RPA. The breakpoints for all covariates in this
analysis were also the same as in RTOG-RPA. However,
recursive partitioning was newly conducted to produce
subgroups of patients whose survival was as homogenous
as possible based on our current data.
For the third and ﬁnal analysis, we ﬁt a tree model to our
cohort using an expanded set of predictors, including those
in RTOG-RPA. The complete list of these predictors
includes age, race, Karnofsky Performance Status (KPS),
histology(GBMorAA),neurologicfunctionalclassiﬁcation
(class 1: able to work or class 2: able to be at home and
classes 3: hospitalized), surgery type (biopsy or Gross total
resection/subtotal resection), IMRT dose, hospital admis-
sion during IMRT, IMRT treatment breaks, tumor location,
the presence or absence of coexisting medical conditions
(diabetes mellitus, hypertension, cardiac disease), tobacco
use, duration of TMZ treatment, duration of 13 neurologic
signs and symptoms, and the presence or absence of each
neurologic symptom. Those neurologic signs and symptoms
were cerebral deﬁcit, cranial nerve deﬁcit, memory lag,
personality change, seizure history, sensory deﬁcit, motor
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123deﬁcit, papilledema, somnolence, speech impairment,
headache, and mental status changes. Chemotherapy was
not one of the treatment-related factors considered because
all patients received TMZ.
The recursive partitioning model uses the rpart function
in R statistical software [19] to identify the optimal split
across all variables and across all possible cutoffs of each
sorted variable. The optimality of a given split is judged
using exponential scaling [20] to assess the log-likelihood
deﬁned by LeBlanc and Crowley [21]. Patients are then
partitioned into the resulting subgroups, one with longer
overall survival and one with shorter overall survival. This
partitioning process is repeated until it produces terminal
nodes that perfectly discriminate survival from death, or
until the data cannot be partitioned further (i.e., n\10
within subgroup). It should be noted that the given method
does not utilize signiﬁcance tests or P-values, but rather
represents a computational approach to estimate the ﬁnal
subsets which are as homogeneous as possible in terms of
survival. Inclusion or exclusion of a given variable from the
tree therefore does not represent the presence or absence of
statistical signiﬁcance. All statistical analyses were con-
ducted with R statistical software.
For terminal nodes resulting from recursive partitioning
with similar survival distributions, we combined these
nodes using the following algorithm: (1) order subgroups
from shortest to longest median survival, (2) conduct the
log-rank test between adjacent curves (i.e., with the most
similar survival distributions), (3) combine nodes with non-
signiﬁcant results between them, unless they both originate
from the same ﬁnal split forming the given two terminal
nodes, (4) reproduce the survival curves and related sta-
tistics (median survival, 2-year survival estimates) using
the subsequently formed sub-groups. Overall survival
outcomes in the combined recursively partitioned model
were tested with the Harrington–Fleming test to determine
if survival of the resulting risk classes were signiﬁcantly
different from each other.
Results
Patient and treatment demographics
Of the 176 patients treated with IMRT and TMZ between
March 2004 and March 2009, 159 were evaluable for
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Fig. 1 Published RTOG-RPA displaying 12 terminal nodes com-
bined into six signiﬁcantly different survival classes (P\0.01). Our
survival results are displayed below the corresponding RTOG-RPA
risk class. BT biopsy, Part/Tot subtotal resection/gross total resection,
Neuro FCT neurological function
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123inclusion in this analysis. Of the 159 patients, 114 had
GBM and 45 had AA (Table 1). Nearly two-thirds of
patients were 50 years of age or older and approximately
54% had tumors with a diameter less than 5.0 cm. Ninety-
ﬁve percent of all patients had a neurologic functional class
of 1 or 2 and 79% had KPS equal to 70 or greater. The most
common of the 13 neurologic signs and symptoms expe-
rienced in our cohort were headache (42.1%), impaired
speech (29.6%), abnormal mental status (27.7%), and sei-
zures (26.4%). Treatment-related characteristics are listed
in Table 2. Approximately 64% of patients underwent a
partial (STR) or gross total resection (GTR) and 87%
received a total radiation dose in excess of 54.4 Gy (range
28–68 Gy). KPS was assigned by the treating physicians
(radiation oncologist or neuro-oncologist) in 123 of 159
patients. In the remainder, KPS was assigned based on
application of the standard scale to all available clinical
records from the time of initial radiation oncology and/or
neurologic oncology evaluation. The overall median sur-
vival was 14.9 months (range, 1.54–83.7 months).
Survival by RTOG-RPA risk group
Each of the 159 patients was assigned to one of the six risk
classes as dictated by the pretreatment and treatment-
related prognostic markers in the RTOG-RPA risk tree
(Fig. 1). The median survival and 2-year survival rates are
presented by RTOG-RPA group (Table 3). In terms of
median survival, the risk groups retained their relative
Table 1 Patient demographics and tumor characteristics
Characteristic Percent of assessable patients (no.)
Gender
Men 61 (97)
Women 39 (62)
Age (years)
\40 19.4 (31)
40–49 15.7 (25)
50–59 30.2 (48)
C60 34.6 (55)
Race
White 94.3 (150)
Other 5.7 (9)
Symptom duration (months)
\2 52.2 (83)
2–4 22.6 (36)
C4 25.2 (40)
Neurological class
1 Work 28.3 (45)
2 Home 66.7 (106)
3 Hospital 5.0 (8)
Karnofsky Performance Status
\70 20.8 (33)
70–80 55.3 (88)
90–100 23.9 (38)
Tumor size (cm)
\5.0 54.1 (86)
C5.0 45.9 (73)
Tumor pathology
GBM 71.7 (114)
AA 28.3 (45)
Tumor location
Frontal 31.4 (50)
Parietal 16.4 (26)
Temporal 30.8 (49)
Occipital 1.9 (3)
Other 19.5 (31)
GBM glioblastoma, AA anaplastic astrocytoma
Table 2 Treatment characteristics
Characteristic Percentage of assessable patients
Extent of surgery
Gross total resection 33.9 (54)
Subtotal resection 30.2 (48)
Biopsy only 35.9 (57)
Total RT dose (Gy)
B54.4 12.6 (20)
[54.4 87.4 (139)
Table 3 Survival by RTOG-RPA risk class in our cohort (A) com-
pared to Curran et al. [3] (B)
Class (number
of patients)
Median survival,
months (IQ range)
2-Year
survival %
(A)
I (25) 31.0 (18.7–47.2) 93.8
II (7) 27.5 (16.4–45.6) 66.7
III (8) 25.0 (17.4–32.0) 66.7
IV (40) 17.7 (12.4–23.7) 31.3
V (62) 10.8 (5.9–16.9) 11.5
VI (17) 6.4 (4.9–11.2) 6.3
(B)
I (139) 58.6 76
II (34) 37.4 68
III (175) 17.9 35
IV (457) 11.1 15
V (395) 8.9 6
VI (263) 4.6 4
RTOG-RPA risk groups II and IV were excluded from further anal-
ysis due to small sample size
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123prognostic ordering. In addition, the overall difference in
survival curves was highly signiﬁcantly different
(P\0.01, v
2 statistic = 70) across all risk groups (Fig. 2).
In terms of 2-year survival and overall survival curves
across all time points, the prognostic ordering was also
retained with the exception of the survival curves of groups
II (n = 7) and III (n = 8) which crossed at three time
points. However, risk group II had a higher survival per-
centage at last follow-up.
Recursive partitioning by RTOG-RPA predictors
All 159 patients were newly recursively partitioned based
on only the treatment and pre-treatment variables in the
published RTOG-RPA. In the original RTOG-RPA, the
most signiﬁcant split was at age 50. In the present cohort,
the most signiﬁcant split was KPS (Fig. 3). Those who had
KPS 90 or greater had a median survival of 25.1 months
and those with KPS worse than 90 had a median survival of
11.8 months. For those with KPS 90 or better, the next split
was histology. Patients with KPS C90 and GBM had a
median survival of 21.3 months whereas those with KPS
C90 and AA had a median survival of 27.7 months. For
those who had KPS below 90, the next splits were at KPS
70 followed by age 50.
The recursive partitioning process produced seven ter-
minal nodes. By the log-rank test, non-signiﬁcant survival
differences were identiﬁed between three terminal node
pairs. Following consolidation of these nodes, four risk
classes remained with median survivals of 29.2, 21.1, 14.6,
and 8.0 months, respectively. The corresponding 2-year
actuarial survival rates were 100, 48, 20, and 2.1%. The
Kaplan–Meier survival curves of the four remaining risk
classes were highly signiﬁcantly different from each other
(P\0.001, v
2 statistic = 111, Fig. 4).
Recursive partitioning with expanded predictors
All 159 patients were again recursively partitioned. How-
ever, this analysis was completed with the predictors in the
RTOG-RPA plus several additional treatment and
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Fig. 2 Kaplan–Meier survival analysis by RTOG-RPA risk classes
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Fig. 3 Recursive partitioning
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RPA. Seven terminal nodes
were combined into four
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below the corresponding risk
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123pre-treatment variables. In this analysis, the most signiﬁ-
cant factor was KPS of 90 (Fig. 5). For those with KPS 90
or greater, the next most signiﬁcant factor was histology.
Patients with KPS C90 and AA were further split based on
the anatomic location of their tumor. Patients with AA,
KPS C90, and tumors located in the frontal lobe (n = 15,
median survival 39.8 months) had signiﬁcantly better sur-
vival than those with KPS C90, AA, and tumors located
elsewhere in the brain (n = 9, median survival
27.5 months), contributing to risk classes I and II,
respectively.
The recursive partitioning process produced 10 terminal
nodes. By the log-rank test, non-signiﬁcant survival dif-
ferences were identiﬁed between three terminal node pairs.
Following consolidation of these nodes, six risk classes
remained with median survivals of 39.8, 25.0, 21.3, 14.8,
8.0, and 5.2 months, respectively. The corresponding
2-year survival rates were 100, 73, 63, 21, 4.6, and 0%. The
Kaplan–Meier survival curves of these six remaining
classes were highly signiﬁcantly different from each other
(P\0.001, v
2 = 147, Fig. 6).
Discussion
Multiple clinical trials of TMZ in combination with radi-
ation therapy (RT) have provided clear evidence that its
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Fig. 4 Kaplan–Meier survival analysis of four risk classes resulting
from new recursive partitioning of our cohort (N = 159) by the
variables in RTOG-RPA
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Fig. 5 Recursive partitioning of 159 patients using the expanded set
of prognostic variables. Ten terminal nodes were combined into six
signiﬁcantly different survival classes (P\0.01). The survival
outcomes are displayed below the corresponding risk class. KPS
Karnofsky Performance Status, XRT radiation therapy
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123addition to RT after optimal surgical resection provides a
clinically signiﬁcant survival advantage compared to
deﬁnitive or postoperative RT alone for high-grade glioma
[11, 16–18]. However, neither these trials nor prior trials of
other adjuvant treatments have shown as great an impact on
survival as the pre-treatment and treatment-related factors
in the RTOG-RPA risk classes [3]. Because concurrent and
adjuvant TMZ have since become the standard of care for
high-grade gliomas, we sought to validate the RTOG-RPA
in a cohort of patients who were all treated with IMRT and
TMZ. The continued validation of RTOG-RPA is highly
valuable because it has been a critical tool in the design and
interpretation of phase II trials and for stratiﬁcation in
phase III trials [4–14].
By assigning RTOG-RPA risk class to each patient in
our cohort, we found these classes retained their relative
prognostic signiﬁcance. This result is similar to the partial
validation of a modiﬁed version of the RTOG-RPA (classes
III, IV, V) by the European Organization for Research and
Treatment of Cancer (EORTC) via secondary analysis of
the EORTC 26981/22981-NCIC CE3 phase III randomized
trial of radiation therapy and concurrent and adjuvant TMZ
[17, 22]. In the EORTC study, median survival times (17,
15 and 10 months for classes III–V, respectively) were
comparable to those of the corresponding RTOG-RPA risk
classes in our cohort. However, the key distinction between
the modiﬁed EORTC-RPA and the RTOG-RPA used in our
analysis is the performance status and mental status scales
used in the underlying clinical trials. In addition to exam-
ining only classes III–V, another difference between the
EORTC validation and our analysis is that their partial
validation was conducted from a cohort in which only
approximately 50% of the patients received TMZ. Fur-
thermore, all patients in the EORTC analysis had GBM and
all were treated with 3D-conformal radiation therapy rather
than IMRT.
Considering the total size of the present cohort
(N = 159), validation of RTOG-RPA not surprisingly
resulted in a limited number of patients in risk class II and
III (n = 7 and n = 8, respectively) and in some variation
in the ordering of the survival curves of those classes.
However, consistent with RTOG-RPA, the median survival
of risk class II was longer than that of risk class III, as was
its survival curve during the majority of follow-up time.
For all other risk classes, the survival results retained the
prognostic ordering of RTOG-RPA throughout the follow-
up period. In our analysis, risk classes III–VI had greater
survival than the corresponding classes in the original
RTOG-RPA analysis by Curran et al. [3]. Similarly, in the
EORTC-modiﬁed partial RPA validation, patients who
received TMZ had longer median and 2-year survival than
those who received RT only in classes III–V [22]. Some-
what surprisingly, classes I and II had shorter survival than
in the original series, although the likelihood of such a
ﬁnding is increased by the overall size of this cohort.
Another, more recently published partial validation of
the RTOG-RPA also focused only on the classiﬁcation of
GBM patients (AA excluded). In this study, all patients
were derived from the RTOG glioma database and all
received radiation plus carmustine in trials from 1974 to
1995 [23]. This analysis revealed that modiﬁcations to
RTOG-RPA classes III–VI did not increase the explained
variation of survival in their cohort. However, the authors
favored combining classes V and VI, leaving only four
prognostic factors (age, performance status, extent of
resection, and neurologic function), to simplify the appli-
cation of RPA to GBM patients despite achieving no
improvement in prognostic performance. Applying this
simpliﬁed model to the RTOG glioma database, produced
median survival times (17.1, 11.2 and 7.5 months for risk
classes III, IV, and V ? VI, respectively) that are also
comparable to the corresponding RTOG-RPA risk classes
in our cohort. The recent RTOG and EORTC validations
[22, 23] and our analysis which together are comprised of
data collected over decades in which radiation therapy,
chemotherapy, and diagnostic techniques have advanced
greatly indicate that the pretreatment patient and tumor
characteristics initially described and organized by Curran
et al. [3] likely continue to have a greater impact on out-
come than do most treatment factors.
Several cooperative group trials and single-institution
analyses of high-grade gliomas have identiﬁed perfor-
mance status, histopathology (GBM or AA), and patient
age as prognostic markers of patient survival with and
without the use of recursive partitioning techniques [3, 7,
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from recursive partitioning of our cohort (N = 159) by the variables
in RTOG-RPA plus an expanded set of predictors
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12322–26]. Our results are consistent with these past ﬁndings.
However, compared to the RTOG-RPA, new recursive
partitioning of our cohort based on the treatment and pre-
treatment prognostic markers in RTOG-RPA, resulted in
four signiﬁcantly different risk classes with KPS rather
than age as the most prognostic or initial branch point of
the risk tree. Consistent with RTOG-RPA, onset of neu-
rological symptoms greater than 3 months prior to surgery
had a protective prognostic role and has been speculated to
reﬂect relatively less aggressive disease [3]. Survival
analysis based on these four risk groups produced greater
separation of each groups’ Kaplan–Meier curve compared
to those produced by assigning RTOG-RPA class to each
patient in our cohort. This increased prognostic power is
quantiﬁed in the greater v
2 statistic (111 compared to 70,
respectively). In both the recently published RTOG anal-
ysis [23] and another recursive partitioning analysis limited
to GBM patients enrolled in clinical trials prior to the TMZ
era [7], the importance of KPS at presentation and patient
age as prognostic markers was also seen. Furthermore,
similar to our results, the impact of stratiﬁcation of KPS at
70 on survival has also been described in the neurosurgical
literature [27, 28].
The new recursive partitioning of our cohort based both
on treatment and pre-treatment variables in RTOG-RPA in
addition to the several additional variables outlined above,
similarly resulted in KPS as the most signiﬁcant or initial
branch point of the risk tree. Some additional prognostic
markers that do not appear in RTOG-RPA include tumor
location, hospital admission during radiation therapy treat-
ment, and history of tobacco use. While there is some con-
troversy regarding the survival beneﬁt of cytoreductive
surgery prior to radiation therapy and TMZ [29–31], our
ﬁnding that tumor location (frontal lobe) partitioned those
with relatively good prognosis into risk groups I or II, is an
interesting ﬁnding that could be further evaluated in a larger
cohort. However, while tumor location has been reported to
predict survival in prior analyses [11, 15], the number of
patients subjecttothisdecisionpointwouldbesmallinmost
clinical trials. The appearance of tobacco use as a marker of
worse survival in malignant glioma patients with poor-
functional status is new and as such is subject to uncertainty
regarding its prognostic value. Secondary recursive parti-
tioning analysis of multi-institutional clinical trials of gli-
omapatients fromtheTMZeracouldpotentiallysuggest the
need for adjustments to RTOG-RPA or conﬁrm the superior
prognostic power of RTOG-RPA in its current form.
Although this is a retrospective review spanning 5 years
and as such is subject to all the usual limitations, approx-
imately one-third of these patients received TMZ on pro-
spective clinical trials and thus underwent more rigorous
monitoring in follow-up. Additional limitations of this
study are inherent to the exploratory nature of recursive
partitioning analysis. While this statistical technique has
gained popularity in recent years because it can place
patients in clearly deﬁnable risk categories, it is a non-
parametric test with limitations. A statement of the prob-
ability that patients in a particular terminal node will
survive to a given date cannot be made because of the
nonparametric and post-hoc nature of this technique. In
addition, the precise pattern of selection of prognostic
factors can vary with only small changes in the group under
study. This can occur if two or more variables have very
similar prognostic power or are highly correlated. Lastly,
the recursive partitioning technique may split a risk group
on a variable that creates terminal nodes with survival
distributions that are not signiﬁcantly different from each
other. However, such variables could be signiﬁcant pre-
dictors of survival via traditional survival analyses.
Since the creation of the RTOG-RPA, it has been
increasingly recognized that not all patients with high-
grade glioma have the same prognosis. Interest in prog-
nostically-important molecular markers and the develop-
ment of targeted therapies is now emerging, as evident in
several recent series [32–37]. In addition to the partial RPA
validation, three nomograms were produced from the
EORTC/NCIC clinical trial to predict outcomes for indi-
vidual patients with newly diagnosed GBM [34]. An
advantage of these nomograms is the potential for more
individualized and more accurate prediction of a particular
patient’s survival than can be obtained from RPA. How-
ever, the major limitation of the nomograms is that their
prognostic utility has yet to be validated in separate inde-
pendent datasets. In the nomogram for patients who
received RT and TMZ, the same prognostic factors as those
in RTOG-RPA were recognized (performance status, age,
mental status, and extent of resection). However, the
EORTC/NCIC glioma clinical trial dataset allowed for the
creation of a nomogram including additional prognostic
factors not examined in the RTOG RPA model such as
MGMT methylation status which was ﬁrst established by
Hegi et al. [35] to signiﬁcantly impact outcomes of patients
receiving alkylating chemotherapy like TMZ.
In addition to MGMT methylation status, another area of
active investigation is gene proﬁling using DNA micro-
arrays to identify gene expression patterns that may classify
glioma tumors into prognostic groups [38]. From this anal-
ysis, AA has been separated into three prognostic subclasses
corresponding to the stages in neurogenesis: proneural,
proliferative, and mesenchymal. Recurrent tumors dis-
played a tendency to shift toward the mesenchymal subclass
which was shown to have the worst prognosis [38].
More recently, biomarkers such as PTEN and EGFR
have been investigated as potential prognostic markers in
GBM. Also whole-genome sequencing of GBM samples
has identiﬁed an R132H (arginine to histidine) somatic
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123mutation in the isocitric dehydrogenase-1 (IDH1) gene that
has been shown to be present in more than 80% of grade II
and grade III gliomas [39–43]. Subsequent studies have
implicated the IDH1 R132H mutation in the early patho-
genesis of glioma by acting in a dominant-negative manner
to produce an approximately 100-fold elevation in levels of
2-hydroxyglutarate, a known onco-metabolite in human
glioma samples [39–43]. Further elucidation of this path-
way may establish serum markers for earlier diagnosis of
low-grade glioma prior to malignant transformation or
novel targets for chemotherapeutic intervention. Once the
prognostic utility of each of the above markers is more
fully understood, additional modiﬁcations to RPA or the
EORTC nomograms will likely be required. The collection
of these studies suggests that more precise estimates of
patients’ risks soon after diagnosis based on both clinical
predictors and some combination of molecular markers
will be possible and that eventually customized, targeted
treatments have the potential to be established for high-
grade glioma.
Our validation of RTOG-RPA suggests that it maintains
prognostic signiﬁcance and should continue to be used to
predict individual patient outcomes for those treated with
IMRT and TMZ and for interpretation and stratiﬁcation of
clinical trials. Although new recursive partitioning of our
cohort indicates that KPS may be more prognostic in
patients treated with TMZ than it was in RTOG-RPA, the
relatively small size (N = 159) of our cohort compared to
the original analysis by Curran et al. [3] suggests potential
modiﬁcations to this classiﬁcation that should be further
explored through analysis of a larger cohort.
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